Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

By L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazières, Keunchil Park, David C. Smith, Á. Artal-Cortés, C. Lewanski and 8 more. The Lancet, 2016

2,545 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/1272e3c6b03bcb951d1fd0f00e8518863e53f175

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project (2017, methodology): “In addition to TCs, Genentech/Roche also includes a measure of infiltrating PD-L1–positive immune cells (ICs) as part of the scoring guideline the SP142 assay for atezolizumab (see Table 1).(9,10) These scoring approaches were determined on the basis of predictive value and clinical data from indivi”
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry (2019, positive): “Nevertheless, data obtained from subgroups in clinical trials [9, 10, 12] and from investigators observations have shown rather weak activity of ICI in NSCLC patients harboring actionable driver mutations [13].”
Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients (2019, neutral): “…signatures and hallmark geneset signatures (Extended Data Figure 5), immune activity signatures, including signatures of cytolytic 21 and cytotoxic 19 activity, interferon-gamma and T-effector cells 18,35 , immune chemokines 38 , and single-cell derived immune cell signatures 42 clustered together.”
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma (2018, neutral): “38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, methodology): “This approval is based on two trial results, Phase III OAK [80] and Phase II POPLAR [81] (Category 1).”